Breaking News

MilliporeSigma Invests €300M in New Bioprocessing Facility in South Korea

Will support biotech and pharmaceutical companies in process development, clinical research, and commercial manufacturing of biologics.

Author Image

By: Charlie Sternberg

Associate Editor

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has invested more than €300 million ($325 million) into a new Bioprocessing Production Center in Daejeon, South Korea.   The large investment in Asia-Pacific demonstrates the company’s commitment to expanding its capacities in the fast-growing region. The investment is expected to create approximately 300 additional jobs by the end of 2028.   “The Asia-Pacific region is home to a large number of inst...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters